1. The Generalisability of Pharmacoeconomic Studies

   • James M. Mason
   • Anne R. Mason

   Current Opinion 09 October 2012 Pages: 937 - 945

2. QALYs

   • Maurice McGregor
   • J. Jaime Caro

   Current Opinion 09 October 2012 Pages: 947 - 952

3. Should We Abandon QALYs as a Resource Allocation Tool?

   • Sandeep Vijan

   Commentary 09 October 2012 Pages: 953 - 954

4. Therapeutic Options for the Prevention and Treatment of Postoperative Nausea and Vomiting

   • Jean Lachaine

   Review Article 09 October 2012 Pages: 955 - 970

   

5. Single-Inhaler Combination Therapy for Asthma

   • Manabu Akazawa
   • David A. Stempel

   Review Article 09 October 2012 Pages: 971 - 988

   

6. Disability and Quality of Life in Post-Traumatic Stress Disorder

   • Soraya Seedat
   • Christine Lochner
   • Dan J. Stein

   Review Article 09 October 2012 Pages: 989 - 998

   

7. Hospitalisation Costs of Cystic Fibrosis

   • Jonas Schreyögg
   • Helge Hollmeyer
   • Reinhard Busse

   Original Research Article 09 October 2012 Pages: 999 - 1009

   

8. The Initial Validation of a Markov Model for the Economic Evaluation of (New) Treatments for Rheumatoid Arthritis

   • Paco M. J. Welsing
   • Johan L. Severens
   • Roland F. J. M. Laan

   Original Research Article 09 October 2012 Pages: 1011 - 1020

   

9. The Cost Effectiveness of Anticoagulation Management Services for Patients with Atrial Fibrillation and at High Risk of Stroke in the US

   • Patrick W. Sullivan
   • Thomas W. Arant
   • Heather Ulrich

   Original Research Article 09 October 2012 Pages: 1021 - 1033

   

10. Anticoagulation for Stroke Prevention

    • Eduard Shantsila
    • Timothy Watson
    • Gregory Y. H. Lip

    Commentary 09 October 2012 Pages: 1035 - 1038